Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report

Pancreatic cancer is the leading cause of cancer death, and treatment options are limited and mostly ineffective. The patient we report had an EGFR exon 19 deletion and had disease progression in the short term after receiving three front-line treatment regimens. We administered furmonertinib and ob...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Xiaoting, Liu, Xiu, Ou, Kai, Zhang, Manman, Gao, Lizhen, Yang, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117981/
https://www.ncbi.nlm.nih.gov/pubmed/37091175
http://dx.doi.org/10.3389/fonc.2023.1151178
_version_ 1785028709197021184
author Ma, Xiaoting
Liu, Xiu
Ou, Kai
Zhang, Manman
Gao, Lizhen
Yang, Lin
author_facet Ma, Xiaoting
Liu, Xiu
Ou, Kai
Zhang, Manman
Gao, Lizhen
Yang, Lin
author_sort Ma, Xiaoting
collection PubMed
description Pancreatic cancer is the leading cause of cancer death, and treatment options are limited and mostly ineffective. The patient we report had an EGFR exon 19 deletion and had disease progression in the short term after receiving three front-line treatment regimens. We administered furmonertinib and observed tumor shrinkage, decreased CA19-9. The progression-free survival (PFS) of furmonertinib was 4.7 months, and no adverse effects were observed. However, the patient did not benefit from subsequent nimotuzumab-based therapy. Targeted therapy driven by the detection of genetic signatures in this patient shows potential clinical benefit in refractory advanced pancreatic cancer.
format Online
Article
Text
id pubmed-10117981
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101179812023-04-21 Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report Ma, Xiaoting Liu, Xiu Ou, Kai Zhang, Manman Gao, Lizhen Yang, Lin Front Oncol Oncology Pancreatic cancer is the leading cause of cancer death, and treatment options are limited and mostly ineffective. The patient we report had an EGFR exon 19 deletion and had disease progression in the short term after receiving three front-line treatment regimens. We administered furmonertinib and observed tumor shrinkage, decreased CA19-9. The progression-free survival (PFS) of furmonertinib was 4.7 months, and no adverse effects were observed. However, the patient did not benefit from subsequent nimotuzumab-based therapy. Targeted therapy driven by the detection of genetic signatures in this patient shows potential clinical benefit in refractory advanced pancreatic cancer. Frontiers Media S.A. 2023-04-06 /pmc/articles/PMC10117981/ /pubmed/37091175 http://dx.doi.org/10.3389/fonc.2023.1151178 Text en Copyright © 2023 Ma, Liu, Ou, Zhang, Gao and Yang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Ma, Xiaoting
Liu, Xiu
Ou, Kai
Zhang, Manman
Gao, Lizhen
Yang, Lin
Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report
title Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report
title_full Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report
title_fullStr Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report
title_full_unstemmed Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report
title_short Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report
title_sort advanced pancreatic cancer with kras wild-type and egfr-sensitive mutation respond favorably to furmonertinib: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117981/
https://www.ncbi.nlm.nih.gov/pubmed/37091175
http://dx.doi.org/10.3389/fonc.2023.1151178
work_keys_str_mv AT maxiaoting advancedpancreaticcancerwithkraswildtypeandegfrsensitivemutationrespondfavorablytofurmonertinibacasereport
AT liuxiu advancedpancreaticcancerwithkraswildtypeandegfrsensitivemutationrespondfavorablytofurmonertinibacasereport
AT oukai advancedpancreaticcancerwithkraswildtypeandegfrsensitivemutationrespondfavorablytofurmonertinibacasereport
AT zhangmanman advancedpancreaticcancerwithkraswildtypeandegfrsensitivemutationrespondfavorablytofurmonertinibacasereport
AT gaolizhen advancedpancreaticcancerwithkraswildtypeandegfrsensitivemutationrespondfavorablytofurmonertinibacasereport
AT yanglin advancedpancreaticcancerwithkraswildtypeandegfrsensitivemutationrespondfavorablytofurmonertinibacasereport

Ejemplares similares